The rapid adoption of GLP-1-based medications represents a paradigm shift in obesity treatment and in healthcare more broadly, offering efficacy for some patients that approaches that of surgical interventions. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.